Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial

Arthritis and Rheumatism

Volumn 56, Issue 2, 2007, Pages 476-488

  Gladman, Dafna D ^a,h   Mease, Philip J ^b   Ritchlin, Christopher T ^c   Choy, Ernest H S ^d   Sharp, John T ^e   Ory, Peter A ^f   Perdok, Renee J ^g   Sasso, Eric H ^g  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Southwest Medical Imaging   (United States)

^g ABBOTT LABORATORIES   (United States)

^h TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLOIDOSIS; ARTHRODESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DISABILITY; DISEASE SEVERITY; DIVERTICULITIS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVALUATION; FEMALE; FOOT DISEASE; FOOT RADIOGRAPHY; GASTROENTERITIS; HAND RADIOGRAPHY; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HUMAN; IMAGE ANALYSIS; INJECTION SITE REACTION; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MECKEL DIVERTICULUM; NASAL SEPTUM DISORDER; NEPHROLITHIASIS; NOSE DISEASE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; PSORIATIC ARTHRITIS; RATING SCALE; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SCORING SYSTEM; SHARP SCORE; SIDE EFFECT; TOE ARTHRODESIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHROGRAPHY; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847032894     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22379     Document Type: Article

References (43)

1. Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life Study. Acta Derm Venereol 2002;82:108-13.
2. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:ii14-7.
3. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PsA): an analysis of 220 patients. Q J Med 1987;62:127-41.
4. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Invest Drugs 2000;9:1511-22.
5. Torre Alonso JC, Rodriguez PA, Arribas Castrillo JM, Ballino Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of ISO patients. Br J Rheumatol 1991;30:245-50.
6. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003;42:1460-8.
7. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12.
8. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-year prospective study. Rheumatology (Oxford) 2003;42:778-83.
9. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. Ann Rheum Dis 2003;62:68-70.
10. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995;22:675-9.
11. Siannis F, Farewell VT, Cook RJ, Schentag CT, Gladman DD. Clinical and radiological damage in psoriatic arthritis. Ann Rheum Dis 2006;65:478-81.
12. Offidani A, Cellini A, Valeri G, Giovagnoni A. Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray findings. Acta Derm Venereol 1998;78:463-5.
13. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72.
14. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10.
15. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
16. Abu-Shakra M, Gladman DD, Thorne JC, Long J, Gough J, Farewell VT. Long-term methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995;2:241-5.
17. Lee JC, Gladman DD, Schentag CT, Cook RJ. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol 2001;7:160-5.
18. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
19. Mader R, Gladman DD, Long J, Gough J, Farewell VT. Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med 1995;18:139-43.
20. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G. The use of sulfasalazine in psoriatic arthritis: a clinical experience. J Rheumatol 1998;25:1957-61.
21. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
22. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72.
23. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
24. Antoni C, Krueger GG, de Vlam K, Birbara C, Bentler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7.
25. Van der Heijde D, Kavanaugh A, Beutler A, Guzzo C, Zhou B, Dooley L, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: results for IMPACT 2 trial [abstract]. Ann Rheum Dis 2005;64:109.
26. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
27. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006;65:1038-43.
28. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:3-10.
29. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
30. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
31. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J Rheumatol 1982;9:789-93.
32. Sharp JT, Bluhm GB, Brook A, Brower AC, Corbett M, Decker JL, et al. Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum 1985;28:6-24.
33. Van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005;64 Suppl 2:ii61-4.
34. Bruynesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change? Ann Rheum Dis 2004;64:179-82.
35. Mease PJ, Ganguly R, Wanke L, Yu E, Singh A. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004;63 Suppl 1:391-2.
36. Goldsmith CH, Boers M, Bombardier C, Tugwell PJ. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. Rheumatology (Oxford) 1993;20:561-5.
37. Smolen JS, van der Heijde DM, St.Clair EW, Emery P, Bathon JM, Keystone E. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
38. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
39. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-81.
40. Keystone ED, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 2004;50:1400-11.
41. Van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16.
42. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
43. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (Humira) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:889-94.